Business Context and Reporting Period
Company: BioLineRx Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2012
Jurisdiction: Israel (incorporated); ADSs listed on Nasdaq Capital Market
Business Overview: BioLineRx is a clinical-stage biopharmaceutical development company focused on identifying, in-licensing, and developing therapeutic candidates. The company has no approved products and generates no product revenue. Its strategy relies on out-licensing candidates to third parties or developing them internally. As of the reporting date, the pipeline included six clinical-stage candidates (BL-1020, BL-1040, BL-5010, BL-7040, BL-8040, BL-1021) and six preclinical candidates.
Key Financial Metrics (Year Ended Dec 31, 2012)
| Metric | Value (NIS '000s) | Value (USD '000s) |
|---|---|---|
| Revenues | 0 | 0 |
| Net Loss | (76,270) | (20,432) |
| Operating Loss | (81,557) | (21,847) |
| Research & Development Expenses | (64,304) | (17,226) |
| Cash and Cash Equivalents | 68,339 | 18,307 |
| Short-term Bank Deposits | 11,459 | 3,070 |
| Total Assets | 90,808 | 24,326 |
| Total Liabilities | 34,879 | 9,343 |
| Shareholders' Equity | 55,929 | 14,983 |
| Accumulated Deficit | (444,300) | (119,000 approx) |
Note: USD amounts are translated at the period-end exchange rate of NIS 3.733 per USD. The company reported zero revenue for 2012, having recognized significant licensing revenue in 2010.
Material Changes vs. Prior Period
- Revenue: Remained at zero, consistent with 2011. The company had no product sales or milestone payments recognized in 2012.
- Net Loss: Increased significantly from NIS 50.2 million in 2011 to NIS 76.3 million in 2012. This was driven primarily by a 51% increase in R&D expenses.
- R&D Expenses: Rose from NIS 42.6 million (2011) to NIS 64.3 million (2012). The increase was attributed to the ramp-up of the Phase 2/3 CLARITY clinical trial for BL-1020 and spending on other clinical-stage projects.
- Liquidity: Cash and short-term deposits totaled approximately NIS 79.8 million ($21.4 million) at year-end 2012. This represented a decrease in cash flow from operations (net cash used was NIS 75.1 million) offset by financing activities (net cash provided was NIS 58.9 million, primarily from a February 2012 private placement).
- Outstanding Shares: Increased to 183,713,197 ordinary shares as of December 31, 2012.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management believes existing cash and investment balances (approximately $21.4 million as of Dec 31, 2012) are sufficient to fund operations through the end of 2014. The company expects to continue incurring significant losses as it advances its therapeutic candidates. Future funding requirements depend on clinical trial progress, regulatory approvals, and the success of out-licensing arrangements.
Key Milestones and Events:
- BL-1020 (Schizophrenia): Phase 2/3 CLARITY trial ongoing. An interim analysis was expected in March 2013.
- BL-1040 (Cardiac): Out-licensed to Ikaria. Ikaria commenced the PRESERVATION 1 CE Mark registration trial in late 2011.
- BL-5010 (Skin Lesions): Planning to commence a pivotal CE-Mark registration trial in the second half of 2013.
- BL-7040 (IBD): Phase 2 proof-of-concept study expected to complete in April 2013.
- BL-8040 (AML): Phase 2 clinical trial planned to commence in the second quarter of 2013.
Material Risks:
- History of Losses: The company has never been profitable and has an accumulated deficit of NIS 444.3 million. It may never achieve profitability.
- Regulatory Approval: No therapeutic candidates have received regulatory approval. Failure to obtain approval for any candidate would prevent commercialization.
- Liquidity: The company requires substantial additional capital to complete clinical development. If additional financing is not available, the company may be forced to delay or eliminate programs.
- Dependence on Partners: Commercialization relies heavily on out-licensing partners (e.g., Ikaria for BL-1040). Failure of partners to meet obligations could adversely affect the business.
- Intellectual Property: Most IP is in-licensed from universities and research institutions. Termination of these agreements would prevent commercialization.
- Geopolitical Risk: Operations are based in Israel, exposing the company to regional political and military instability.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the ~$21.4 million cash balance to fund operations through 2014, considering the high burn rate (NIS 76M net loss in 2012).
- BL-1020 Trial Status: Monitor the results of the interim analysis of the CLARITY trial (expected March 2013), which is critical for the company's lead asset.
- Out-Licensing Progress: Assess the status of potential out-licensing deals for BL-1020, BL-5010, BL-7040, and BL-8040, as the company lacks internal commercialization capabilities.
- Ikaria Partnership: Review updates on Ikaria's development of BL-1040, as BioLineRx has limited control over this asset's timeline.
- Government Funding Restrictions: Understand the implications of Israeli Office of the Chief Scientist (OCS) funding, which may restrict the transfer of technology or manufacturing outside Israel and require royalty payments.
- Dilution Risk: Note the active "At-the-Market" (ATM) facility with Lincoln Park Capital (up to $15M) and recent direct placements, which may lead to further share dilution.